AAAAAA
Results:
1-14
|
Results: 14
Authors:
JERLING M
MERLE Y
MENTRE F
MALLET A
Citation: M. Jerling et al., POPULATION PHARMACOKINETICS OF CLOZAPINE EVALUATED WITH THE NONPARAMETRIC MAXIMUM-LIKELIHOOD METHOD, British journal of clinical pharmacology, 44(5), 1997, pp. 447-453
Authors:
HELLGREN U
BERGGRENPALME I
BERGQVIST Y
JERLING M
Citation: U. Hellgren et al., ENANTIOSELECTIVE PHARMACOKINETICS OF MEFLOQUINE DURING LONG-TERM INTAKE OF THE PROPHYLACTIC DOSE, British journal of clinical pharmacology, 44(2), 1997, pp. 119-124
Authors:
JERLING M
Citation: M. Jerling, POPULATION PHARMACOKINETICS AND PHARMACODYNAMICS - POTENTIAL USE FOR GATHERING DOSE-CONCENTRATION-RESPONSE, European journal of drug metabolism and pharmacokinetics, 21(2), 1996, pp. 113-121
Authors:
HELLGREN U
JASTREBOVA J
JERLING M
KRYSEN B
BERGQVIST Y
Citation: U. Hellgren et al., COMPARISON BETWEEN CONCENTRATIONS OF RACEMIC MEFLOQUINE, ITS SEPARATEENANTIOMERS AND THE CARBOXYLIC-ACID METABOLITE IN WHOLE-BLOOD SERUM AND PLASMA, European Journal of Clinical Pharmacology, 51(2), 1996, pp. 171-173
Authors:
JERLING M
DAHL ML
ABERGWISTEDT A
LILJENBERG B
LANDELL NE
BERTILSSON L
SJOQVIST F
Citation: M. Jerling et al., THE CYP2D6 GENOTYPE PREDICTS THE ORAL CLEARANCE OF THE NEUROLEPTIC AGENTS PERPHENAZINE AND ZUCLOPENTHIXOL, Clinical pharmacology and therapeutics, 59(4), 1996, pp. 423-428
Authors:
JERLING M
Citation: M. Jerling, POPULATION-KINETICS OF ANTIDEPRESSANTS AND NEUROLEPTIC DRUGS - STUDIES OF THERAPEUTIC DRUG-MONITORING DATA TO EVALUATE KINETIC VARIABILITY,DRUG-INTERACTIONS, NONLINEAR KINETICS, AND THE INFLUENCE OF GENETIC-FACTORS - JERLING,M, Nordic journal of psychiatry, 49(2), 1995, pp. 146-147
Authors:
JERLING M
Citation: M. Jerling, DOSING OF ANTIDEPRESSANTS - THE UNKNOWN ART, Journal of clinical psychopharmacology, 15(6), 1995, pp. 435-439
Authors:
CARRILLO JA
JERLING M
BERTILSSON L
Citation: Ja. Carrillo et al., INTERACTION BETWEEN CAFFEINE AND CLOZAPINE - COMMENT, Journal of clinical psychopharmacology, 15(5), 1995, pp. 376-377
Authors:
TOMSON T
JERLING M
SUNDQVIST A
Citation: T. Tomson et al., ANTIEPILEPTIC DRUG LEVELS IN THE EMERGENCY DEPARTMENT, Epilepsia, 36, 1995, pp. 154-154
Authors:
JERLING M
MERLE Y
MENTRE F
MALLET A
Citation: M. Jerling et al., POPULATION PHARMACOKINETICS OF NORTRIPTYLINE DURING MONOTHERAPY AND DURING CONCOMITANT TREATMENT WITH DRUGS THAT INHIBIT CYP2D6 - AN EVALUATION WITH THE NONPARAMETRIC MAXIMUM-LIKELIHOOD METHOD, British journal of clinical pharmacology, 38(5), 1994, pp. 453-462
Authors:
JERLING M
LINDSTROM L
BONDESSON U
BERTILSSON L
Citation: M. Jerling et al., FLUVOXAMINE INHIBITION AND CARBAMAZEPINE INDUCTION OF THE METABOLISM OF CLOZAPINE - EVIDENCE FROM A THERAPEUTIC DRUG-MONITORING SERVICE, Therapeutic drug monitoring, 16(4), 1994, pp. 368-374
Authors:
JERLING M
BERTILSSON L
SJOQVIST F
Citation: M. Jerling et al., THE USE OF THERAPEUTIC DRUG-MONITORING DATA TO DOCUMENT KINETIC DRUG-INTERACTIONS - AN EXAMPLE WITH AMITRIPTYLINE AND NORTRIPTYLINE, Therapeutic drug monitoring, 16(1), 1994, pp. 1-12
Authors:
JERLING M
ALVAN G
Citation: M. Jerling et G. Alvan, NONLINEAR KINETICS OF NORTRIPTYLINE IN RELATION TO NORTRIPTYLINE CLEARANCE AS OBSERVED DURING THERAPEUTIC DRUG-MONITORING, European Journal of Clinical Pharmacology, 46(1), 1994, pp. 67-70
Authors:
HELLGREN U
ALVAN G
JERLING M
Citation: U. Hellgren et al., ON THE QUESTION OF INTERINDIVIDUAL VARIATIONS IN CHLOROQUINE CONCENTRATIONS, European Journal of Clinical Pharmacology, 45(4), 1993, pp. 383-385
Risultati:
1-14
|